CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

RegulatoryapprovedZEVASKYNPositive

AI Analysis

Summary

CMS has granted New Technology Add-On Payment (NTAP) status for ZEVASKYN, a therapeutic from Abeona Therapeutics, which provides enhanced reimbursement recognition for the innovative treatment.

Outcome Details

New Technology Add-On Payment (NTAP) status granted by CMS

Importance:7/10

Sentiment:

0.70

regulatory approvalCMSNTAPreimbursementgene therapy

Related Companies

$ABEO

Read the original article

Published by yahoo_finance on August 4, 2026 11:30 AM

Read Original